Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01150526 · ClinicalTrials.gov registry record · Phase 1
Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate
A Phase 1 study, sponsored by Metabolic Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT01150526 is a Phase 1 study that has completed, run by Metabolic Technologies. The registered enrollment target is 41 participants.
The verdict
NCT01150526, a Phase 1 study, has completed, sponsored by Metabolic Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The proposed study will test efficacy of HMB in free acid gel to decrease muscle damage, diminish inflammatory response, and improve muscle strength recovery following an acute exercise stress. HMB in a free acid gel or in CaHMB capsule form will be administered as either a single dose before a bout of acute exercise or in multiple doses (one before and three daily doses for the 4 days following the acute exercise). We hypothesize that HMB in free acid gel will result in less muscle damage, diminished inflammatory response, and improved muscle strength recovery than either a placebo or CaHMB treatment following a bout of acute eccentric exercise. Our endpoints will include measurements of: (1) markers for muscle damage (CPK and LDH); (2) indicators of inflammation (CRP, TNF-α, IL-6, IL-1ra and IL-18); and (3) muscle strength recovery and soreness.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT CaHMB
- DIETARY_SUPPLEMENT HMB Free Acid Gel
- DIETARY_SUPPLEMENT Placebo Gel Dosage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01150526
The ClinicalTrials.gov registry entry for NCT01150526 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metabolic Technologies, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01150526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01150526 about?
NCT01150526 is a clinical study titled "Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate". The proposed study will test efficacy of HMB in free acid gel to decrease muscle damage, diminish inflammatory response, and improve muscle strength recovery following an acute exercise stress. HMB in a free acid gel or in CaHMB capsule form will be administered as either a single dose before a bout...
What is the current status of trial NCT01150526?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2010-10. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01150526?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), CaHMB (DIETARY_SUPPLEMENT), HMB Free Acid Gel (DIETARY_SUPPLEMENT), Placebo Gel Dosage (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01150526?
This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.